The retinoblastoma tumor suppressor promotes efficient human cytomegalovirus lytic replication

Journal of Virology

Volumn 89, Issue 9, 2015, Pages 5012-5021

  VanDeusen, Halena R ^a   Kalejta, Robert F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IE1 PROTEIN; IE2 PROTEIN; PP150 PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA REPLICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IE GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; VIRION; VIROGENESIS; VIRUS ENTRY; VIRUS GENE; VIRUS LATENCY; VIRUS REPLICATION; CELL CULTURE; CYTOMEGALOVIRUS; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY;

HUMAN HERPESVIRUS 5;

CELLS, CULTURED; CYTOMEGALOVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; RETINOBLASTOMA PROTEIN; VIRUS REPLICATION;

EID: 84928524630     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00175-15     Document Type: Article

References (66)

1. Viatour P, Sage J. 2011. Newly identified aspects of tumor suppression by RB. Dis Model Mech 4:581-585. http://dx.doi.org/10.1242/dmm.008060.
2. Di Fiore R, D'Anneo A, Tesoriere G, Vento R. 2013. RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J Cell Physiol 228:1676-1687. http://dx.doi.org/10.1002/jcp.24329.
3. Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA. 1990. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87:2775-2779. http://dx.doi.org/10.1073/pnas.87.7.2775.
4. Morris EJ, Dyson NJ. 2001. Retinoblastoma protein partners. Adv Cancer Res 82:1-54. http://dx.doi.org/10.1016/S0065-230X(01)82001-7.
5. Dick FA, Rubin SM. 2013. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 14:297-306. http://dx.doi.org/10.1038/nrm3567.
6. Nicolay BN, Dyson NJ. 2013. The multiple connections between pRB and cell metabolism. Curr Opin Cell Biol 25:735-740. http://dx.doi.org/10.1016/j.ceb.2013.07.012.
7. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674. http://dx.doi.org/10.1016/j.cell.2011.02.013.
8. Sherr CJ, McCormick F. 2002. The RB and p53 pathways in cancer. Cancer Cell 2:103-112. http://dx.doi.org/10.1016/S1535-6108(02)00102-2.
9. Rubin SM. 2013. Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem Sci 38:12-19. http://dx.doi.org/10.1016/j.tibs.2012.10.007.
10. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. 1999. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98:859-869. http://dx.doi.org/10.1016/S0092-8674(00)81519-6.
11. Trimarchi JM, Lees JA. 2002. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3:11-20. http://dx.doi.org/10.1038/nrm714.
12. Johnson DG. 2000. The paradox of E2F1: oncogene and tumor suppressor gene. Mol Carcinog 27:151-157. http://dx.doi.org/10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C.
13. Johnson DG, Cress WD, Jakoi L, Nevins JR. 1994. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 91:12823-12827. http://dx.doi.org/10.1073/pnas.91.26.12823.
14. Burke JR, Hura GL, Rubin SM. 2012. Structures of inactive retinoblastoma protein reveal multiple mechanisms for cell cycle control. Genes Dev 26:1156-1166. http://dx.doi.org/10.1101/gad.189837.112.
15. Barrientes S, Cooke C, Goodrich DW. 2000. Glutamic acid mutagenesis of retinoblastoma protein phosphorylation sites has diverse effects on function. Oncogene 19:562-570. http://dx.doi.org/10.1038/sj.onc.1203332.
16. Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF. 2014. CyclinDactivates the Rb tumor suppressor by mono-phosphorylation. eLife 3:e02872. http://dx.doi.org/10.7554/eLife.02872.
17. Macdonald JI, Dick FA. 2012. Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function. Genes Cancer 3:619-633. http://dx.doi.org/10.1177/1947601912473305.
18. Huh K, Zhou X, Hayakawa H, Cho J-Y, Libermann TA, Jin J, Harper JW, Munger K. 2007. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 81:9737-9747. http://dx.doi.org/10.1128/JVI.00881-07.
19. Boyer SN, Wazer DE, Band V. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56:4620-4624.
20. Collins AS, Nakahara T, Do A, Lambert PF. 2005. Interactions with pocket proteins contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle. J Virol 79:14769-14780. http://dx.doi.org/10.1128/JVI.79.23.14769-14780.2005.
21. Bodily JM, Mehta KPM, Cruz L, Meyers C, Laimins LA. 2011. The E7 open reading frame acts in cis and in trans to mediate differentiationdependent activities in the human papillomavirus type 16 life cycle. J Virol 85:8852-8862. http://dx.doi.org/10.1128/JVI.00664-11.
22. Roman A, Munger K. 2013. The papillomavirus E7 proteins. Virology 445:138-168. http://dx.doi.org/10.1016/j.virol.2013.04.013.
23. Bagchi S, Raychaudhuri P, Nevins JR. 1990. Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation. Cell 62:659-669. http://dx.doi.org/10.1016/0092-8674(90)90112-R.
24. Sauthoff H, Pipiya T, Heitner S, Chen S, Bleck B, Reibman J, Chang W, Norman RG, Rom WN, Hay JG. 2004. Impact of E1a modifications on tumor-selective adenoviral replication and toxicity. Mol Ther 10:749-757. http://dx.doi.org/10.1016/j.ymthe.2004.07.014.
25. Seifried LA, Talluri S, Cecchini M, Julian LM, Mymryk JS, Dick FA. 2008. pRB-E2F1 complexes are resistant to adenovirus E1A-mediated disruption. J Virol 82:4511-4520. http://dx.doi.org/10.1128/JVI.02713-07.
26. Ferrari R, Gou D, Jawdekar G, Johnson SA, Nava M, Su T, Yousef AF, Zemke NR, Pellegrini M, Kurdistani SK, Berk AJ. 2014. Adenovirus small E1A employs the lysine acetylases p300/CBP and tumor suppressor Rb to repress select host genes and promote productive virus infection. Cell Host Microbe 16:663-676. http://dx.doi.org/10.1016/j.chom.2014.10.004.
27. Cinatl J, Scholz M, Kotchetkov R, Vogel J-U, Doerr HW. 2004. Molecular mechanisms of the modulatory effects of HCMV infection in tumor cell biology. Trends Mol Med 10:19-23. http://dx.doi.org/10.1016/j.molmed.2003.11.002.
28. Soroceanu L, Cobbs CS. 2011. Is HCMV a tumor promoter? Virus Res 157:193-203. http://dx.doi.org/10.1016/j.virusres.2010.10.026.
29. Barami K. 2010. Oncomodulatory mechanisms of human cytomegalovirus in gliomas. J Clin Neurosci 17:819-823. http://dx.doi.org/10.1016/j.jocn.2009.10.040.
30. Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF. 2012. Significant association of multiple human cytomegalovirus genomic loci with glioblastoma multiforme samples. J Virol 86:854-864. http://dx.doi.org/10.1128/JVI.06097-11.
31. Kalejta RF, Bechtel JT, Shenk T. 2003. Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasomedependent degradation of the retinoblastoma family of tumor suppressors. Mol Cell Biol 23:1885-1895. http://dx.doi.org/10.1128/MCB.23.6.1885-1895.2003.
32. Kalejta RF, Shenk T. 2003. Proteasome-dependent, ubiquitinindependent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc Natl Acad Sci USA 100: 3263-3268. http://dx.doi.org/10.1073/pnas.0538058100.
33. Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, Kalejta RF. 2008. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 320:797-799. http://dx.doi.org/10.1126/science.1152095.
34. Cantrell SR, Bresnahan WA. 2005. Interaction between the human cytomegalovirus UL82 gene product (pp71) and hDaxx regulates immediateearly gene expression and viral replication. J Virol 79:7792-7802. http://dx.doi.org/10.1128/JVI.79.12.7792-7802.2005.
35. Prichard MN, Sztul E, Daily SL, Perry AL, Frederick SL, Gill RB, Hartline CB, Streblow DN, Varnum SM, Smith RD, Kern ER. 2008. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol 82:5054-5067. http://dx.doi.org/10.1128/JVI.02174-07.
36. Jacob T, Van den Broeke C, Favoreel HW. 2011. Viral serine/threonine protein kinases. J Virol 85:1158-1173. http://dx.doi.org/10.1128/JVI.01369-10.
37. Poma EE, Kowalik TF, Zhu L, Sinclair JH, Huang ES. 1996. The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2Fresponsive promoter. J Virol 70:7867-7877.
38. Wiebusch L, Asmar J, Uecker R, Hagemeier C. 2003. Human cytomegalovirus immediate-early protein 2 (IE2)-mediated activation of cyclin E is cell-cycle-independent and forces S-phase entry in IE2-arrested cells. J Gen Virol 84:51-60. http://dx.doi.org/10.1099/vir.0.18702-0.
39. Song Y-J, Stinski MF. 2002. Effect of the human cytomegalovirus IE86 protein on expression of E2F-responsive genes: a DNA microarray analysis. Proc Natl Acad Sci USA 99:2836-2841. http://dx.doi.org/10.1073/pnas.052010099.
40. Saffert RT, Kalejta RF. 2007. Human cytomegalovirus gene expression is silenced by Daxx-mediated intrinsic immune defense in model latent infections established in vitro. J Virol 81:9109-9120. http://dx.doi.org/10.1128/JVI.00827-07.
41. Sanchez V, Clark CL, Yen JY, Dwarakanath R, Spector DH. 2002. Viable human cytomegalovirus recombinant virus with an internal deletion of the IE2 86 gene affects late stages of viral replication. J Virol 76:2973-2989. http://dx.doi.org/10.1128/JVI.76.6.2973-2989.2002.
42. Murphy E, Yu D, Grimwood J, Schmutz J, Dickson M, Jarvis MA, Hahn G, Nelson JA, Myers RM, Shenk TE. 2003. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci USA 100:14976-14981. http://dx.doi.org/10.1073/pnas.2136652100.
43. Pasque V, Gillich A, Garrett N, Gurdon JB. 2011. Histone variant macroH2A confers resistance to nuclear reprogramming. EMBO J 30: 2373-2387. http://dx.doi.org/10.1038/emboj.2011.144.
44. Ueno T, Sasaki K, Yoshida S, Kajitani N, Satsuka A, Nakamura H, Sakai H. 2006. Molecular mechanisms of hyperplasia induction by human papillomavirus E7. Oncogene 25:4155-4164. http://dx.doi.org/10.1038/sj.onc.1209445.
45. Nowak B, Sullivan C, Sarnow P, Thomas R, Bricout F, Nicolas JC, Fleckenstein B, Levine AJ. 1984. Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins. Virology 132:325-338. http://dx.doi.org/10.1016/0042-6822(84)90039-4.
46. Saffert RT, Kalejta RF. 2006. Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression. J Virol 80:3863-3871. http://dx.doi.org/10.1128/JVI.80.8.3863-3871.2006.
47. Hwang J, Saffert RT, Kalejta RF. 2011. Elongin B-mediated epigenetic alteration of viral chromatin correlates with efficient human cytomegalovirus gene expression and replication. mBio 2(2):e00023-11. http://dx.doi.org/10.1128/mBio.00023-11.
48. Juckem LK, Boehme KW, Feire AL, Compton T. 2008. Differential initiation of innate immune responses induced by human cytomegalovirus entry into fibroblast cells. J Immunol 180:4965-4977. http://dx.doi.org/10.4049/jimmunol.180.7.4965.
49. Salvant BS, Fortunato EA, Spector DH. 1998. Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription. J Virol 72:3729-3741.
50. Sage J, Miller AL, Pérez-Mancera PA, Wysocki JM, Jacks T. 2003. Acute mutation of retinoblastoma gene function is sufficient for cell cycle reentry. Nature 424:223-228. http://dx.doi.org/10.1038/nature01764.
51. Saffert RT, Penkert RR, Kalejta RF. 2010. Cellular and viral control over the initial events of human cytomegalovirus experimental latency in CD34+ cells. J Virol 84:5594-5604. http://dx.doi.org/10.1128/JVI.00348-10.
52. Hilgendorf KI, Leshchiner ES, Nedelcu S, Maynard MA, Calo E, Ianari A, Walensky LD, Lees JA. 2013. The retinoblastoma protein induces apoptosis directly at the mitochondria. Genes Dev 27:1003-1015. http://dx.doi.org/10.1101/gad.211326.112.
53. Antonucci LA, Egger JV, Krucher NA. 2014. Phosphorylation of the Retinoblastoma protein (Rb) on serine-807 is required for association with Bax. Cell Cycle 13:3611-3617. http://dx.doi.org/10.4161/15384101.2014.964093.
54. Wolf DG, Courcelle CT, Prichard MN, Mocarski ES. 2001. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc Natl Acad Sci USA 98:1895-1900. http://dx.doi.org/10.1073/pnas.98.4.1895.
55. Kamil JP, Hume AJ, Jurak I, Münger K, Kalejta RF, Coen DM. 2009. Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase. Proc Natl Acad Sci USA 106:16823-16828. http://dx.doi.org/10.1073/pnas.0901521106.
56. Hwang E-S, Zhang Z, Cai H, Huang DY, Huong S-M, Cha C-Y, Huang E-S. 2009. Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J Virol 83:12388-12398. http://dx.doi.org/10.1128/JVI.00304-09.
57. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. 1994. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265:391-394. http://dx.doi.org/10.1126/science.8023160.
58. Kwon Y, Kim M-N, Young Choi E, Heon Kim J, Hwang E-S, Cha C-Y. 2012. Inhibition of p53 transcriptional activity by human cytomegalovirus UL44. Microbiol Immunol 56:324-331. http://dx.doi.org/10.1111/j.1348-0421.2012.00446.x.
59. Fortunato EA, Spector DH. 1998. p53 and RPA are sequestered in viral replication centers in the nuclei of cells infected with human cytomegalovirus. J Virol 72:2033-2039.
60. Casavant NC, Luo MH, Rosenke K, Winegardner T, Zurawska A, Fortunato EA. 2006. Potential role for p53 in the permissive life cycle of human cytomegalovirus. J Virol 80:8390-8401. http://dx.doi.org/10.1128/JVI.00505-06.
61. Hannemann H, Rosenke K, O'Dowd JM, Fortunato EA. 2009. The presence of p53 influences the expression of multiple human cytomegalovirus genes at early times postinfection. J Virol 83:4316-4325. http://dx.doi.org/10.1128/JVI.02075-08.
62. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, Nevins JR. 1992. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 89:4549-4553. http://dx.doi.org/10.1073/pnas.89.10.4549.
63. Hayashi ML, Blankenship C, Shenk T. 2000. Human cytomegalovirus UL69 protein is required for efficient accumulation of infected cells in the G1 phase of the cell cycle. Proc Natl Acad Sci USA 97:2692-2696. http://dx.doi.org/10.1073/pnas.050587597.
64. Toropova K, Huffman JB, Homa FL, Conway JF. 2011. The herpes simplex virus 1 UL17 protein is the second constituent of the capsid vertex-specific component required for DNA packaging and retention. J Virol 85:7513-7522. http://dx.doi.org/10.1128/JVI.00837-11.
65. Tandon R, Mocarski ES. 2012. Viral and host control of cytomegalovirus maturation. Trends Microbiol 20:392-401. http://dx.doi.org/10.1016/j.tim.2012.04.008.
66. Bellacchio E, Paggi MG. 2013. Understanding the targeting of the RB family proteins by viral oncoproteins to defeat their oncogenic machinery. J Cell Physiol 228:285-291. http://dx.doi.org/10.1002/jcp.24137.